Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Hexarelin

Examorelin, HEX

Quick Stats
Studies 233
Trials 61
Score 4
1995 pubmed 31 citations

Hexarelin induced growth hormone release is influenced by exogenous growth hormone.

Massoud. A F AF; Hindmarsh. P C PC; Brook. C G CG

Key Findings

  • Hexarelin caused a larger peak GH release than GHRH regardless of prior saline or GH injection.
  • A prior IV bolus of recombinant GH reduced the GH response to both hexarelin and GHRH, showing partial feedback inhibition.
  • The reduction in GH response was slightly less for hexarelin than GHRH, though the difference wasn’t statistically significant; IGF‑I levels didn’t change.

Practical Outcomes

  • Hexarelin can be used as an effective GH secretagogue, but to get the biggest boost, space it away from any exogenous GH doses. It may be a better choice than GHRH‑based peptides for those looking to spike GH without raising IGF‑I immediately.

Summary

Hexarelin is a strong trigger for the body to release growth hormone, even more so than the natural hormone GHRH. Giving a dose of synthetic GH first does dampen the response, but hexarelin still works, just a bit less. This means you can use hexarelin to boost GH, but timing matters—don’t stack it right after a GH shot.

Abstract

Growth hormone releasing peptides (GHRPs) are a group of synthetic compounds capable of releasing GH by an unknown mechanism. The aim of this study was to determine the effect of administering biosynthetic human growth hormone (rhGH) on the GH releasing activity of hexarelin, a new and potent GHRP, and to compare the results with those obtained with growth hormone releasing hormone (GHRH). Boluses of saline or rhGH were administered intravenously, followed 90 minutes later by a second intravenous bolus of saline, hexarelin or GHRH. Studies were performed following an overnight fast. Each subject underwent six studies performed in a random order and separated by at least 2 days. Six healthy adult males (23.8-34.3 years) were studied. Serum GH and IGF-I levels were measured by radioimmunoassay. The peak serum GH response to hexarelin was greater than that to GHRH, irrespective of whether the first bolus was saline (P < 0.05) or rhGH (P < 0.02). Prior administration of rhGH led to a reduction in peak serum GH response to hexarelin or GHRH (P < 0.05); the percentage reduction in response to hexarelin was less than that to GHRH, but this difference was not statistically significant (P = 0.3). There was no change in serum IGF-I concentration before or 90 minutes after the administration of rhGH. Hexarelin is a potent GH secretagogue subject to partial feedback inhibition by rhGH. This raises issues about its mechanism of action and may have implications for its potential therapeutic use.

Study Information

Provider

pubmed

Year

1995

Date

1995-11-01T00:00:00.000Z

DOI

10.1111/j.1365-2265.1995.tb02927.x

Citations

31

References

39